An international observational study validating gene-expression sepsis immune subgroups
Authors' conclusion
Gene-expression diagnostics can identify patients with sepsis at high-risk of poor outcomes
Study context
- Population
- Adults with sepsis in the intensive care unit (ICU), 17 sites in the UK, Sweden and France (March 2021-November 2022)
- Participants
- 357 adults · 17 sites
- Exposure
- High vs low risk groups assigned by 2 gene-expression models
- Outcome
- 90-day mortality by gene-expression risk group
- Follow-up
- Blood at days 2-5 (S1), 6-8 (S2) and 13-15 (S3) after ICU admission
Methodological detailsinternational, multicentre (17 sites), central blood analysis, Recruitment March 2021-November 2022
- International
- Multicentre (17 sites)
- Central blood analysis
- Recruitment March 2021-November 2022
Main finding
As reported in the abstract
90-day mortality, model 1
High-risk (S1) vs Low-risk (S1): P = 0.04 · High-risk (S2) vs Low-risk (S2): P < 0.001 · High-risk (S3) vs Low-risk (S3): P = 0.007
Observational data: associations, not effects.
Further findings
90-day mortality, model 2, S1 · S1 (days 2-5)
P = 0.77
90-day mortality, model 2, S2 · S2 (days 6-8)
P = 0.002
90-day mortality, model 2, S3 · S3 (days 13-15)
P = 0.13
Original publication
An international observational study validating gene-expression sepsis immune subgroups. Crit Care. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →